Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Pharmacyclics Is Ripe For A Major Correction

Pharmacyclics Is Ripe For A Major Correction

Healthcare Sector and Stocks Analysis from Seeking Alpha

Sat, 16 Feb 2013

By John Li : Since February 2012, Pharmacyclics' ( PCYC ) price had a run up of 232%. The company's incredible run up was fueled by ibrutinib's incredible Phase III data results, Johnson & Johnson's ( JNJ ) generous milestone payments, numerous analysts' "buy" recommendations, and ibrutinib's ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Videos

  1. Why J&J Bought a Big Piece of Elan

    Fri, 4 Dec 2009

    Morningstar's Damien Conover and Alex Morozov discuss what J&J's stake in biotech Elan means for both companies.

  2. Upside Attraction to J&J

    Fri, 4 Dec 2009

    Morningstar's Damien Conover discusses the prospects for J&J's stent and drug pipelines.

  3. What Makes a Dividend Stock Tick

    Mon, 28 Dec 2009

    Morningstar's Josh Peters on considering yield and growth when looking for dividend-stock opportunities.

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.